Table 5 Treatment-emergent and treatment-related adverse events (AEs) (n = 30, safety population)
| Â | Formulation | Overall | ||
|---|---|---|---|---|
| Â | A | B | C | Â |
Subjects experiencing a treatment-emergent AE, n (%) | 19/30 (63.3) | 16/29 (55.2) | 18/29 (62.1) | 26/30 (86.7) |
Treatment-emergent AEs, n | 35 | 27 | 29 | 91 |
Treatment-related AEs | Â | Â | Â | Â |
Total, n | 24 | 12 | 20 | 56 |
   Nausea | 12 | 4 | 9 | 25 |
   Headache | 2 | 4 | 5 | 11 |
   Dizziness | 4 | 2 | 2 | 8 |
   Vomiting | 2 | 0 | 1 | 3 |
   Upper abdominal pain | 0 | 1 | 0 | 1 |
   Abdominal pain | 1 | 0 | 0 | 1 |
   Peripheral oedema | 1 | 0 | 0 | 1 |
   Abdominal discomfort | 0 | 0 | 1 | 1 |
   Tachycardia | 1 | 0 | 0 | 1 |
   Pain in extremity | 1 | 0 | 0 | 1 |
   Asthenia | 0 | 1 | 0 | 1 |
   Injection site bruising | 0 | 0 | 1 | 1 |
   Tremor | 0 | 0 | 1 | 1 |